Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. In general, the World Cancer Research Fund International and American Institute for Cancer Research recommend the following: 1) Be physically active each day 2) avoid eating processed foods and try to avoid adding sugar to your foods or drinks 3) Eat mostly plant-based foods and limit red meat and processed meat consumption 4) It is best to ...

    • Early Stage

      Genetic causes, such as the BRCA (pronounced "Bracka")...

  2. Treatment overview. This treatment regimen consists of two parts: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Breast neoadjuvant/adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly. Breast adjuvant TH (DOCEtaxel and trastuzumab) three weekly.

  3. This protocol is part of the AC-TH regimen: 4 cycles of AC, followed by 4 cycles of TH and 13 cycles of trastuzumab. Link to Breast adjuvant AC-TH overview; Link to Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) three weekly; Drug status: Docetaxel is on the PBS general schedule. Trastuzumab is PBS authority

  4. 13 Σεπ 2019 · The NSABP B-31 compared AC-T regimen, i.e., four cycles of doxorubicin plus cyclophosphamide (AC) followed by four sequential cycles of paclitaxel every 3 weeks with AC-TH regimen, i.e ...

  5. 25 Μαΐ 2020 · We wanted to compare the efficacy and safety of the anthracycline regimen EC-TH versus nonanthracycline regimen TCH in neoadjuvant setting for HER2-positive breast cancer.

  6. 7 Δεκ 2022 · INTRODUCTION. The following material represents a subset of chemotherapy and immunotherapy regimens that are used for the treatment of patients with breast cancer, both in the adjuvant and neoadjuvant settings.

  7. 26 Απρ 2016 · Less cardiotoxicity is seen with TCH (docetaxel, carboplatin, and trastuzumab) than with ACTH (doxorubicin and cyclophosphamide→docetaxel and trastuzumab), and TCH is recommended for patients at higher risk for cardiotoxicity.*

  1. Γίνεται επίσης αναζήτηση για